Eli Lilly is expected to report second-quarter 2026 earnings on Thursday that exceed Wall Street consensus estimates, as the pharmaceutical company benefits from soaring demand for its Zepbound and Mounjaro treatments. Analysts polled by LSEG have projected continued double-digit revenue growth for the Indianapolis-based drugmaker.

Lilly has emerged as a leader in the fast-growing market for GLP-1 medicines, which treat obesity and type 2 diabetes. The company has expanded manufacturing capacity across sites in Indiana and North Carolina to address persistent supply constraints, and executives have repeatedly pointed to unmet demand as a driver of future growth.

Investors will focus on updates about Lilly's oral obesity drug, orforglipron, which the company has positioned as a potential blockbuster that could broaden access beyond injectable therapies. Analysts at Morgan Stanley and Bank of America have flagged the pill's regulatory timeline and pricing strategy as key catalysts for the stock.

The results will be closely watched against those of rival Novo Nordisk, whose Wegovy and Ozempic compete directly with Lilly's portfolio. Both companies have faced scrutiny over drug pricing in the United States, and any commentary on guidance or list prices is likely to move shares.

Lilly's stock has been among the best performers in the healthcare sector over the past year. Chief executive David Ricks is expected to address production and pipeline progress during the earnings call scheduled for Thursday morning.